Why Post Cycle Therapy is Necessary Nolva

Bodybuilders and other athletes often take steroids to help with fat loss and to enhance muscle growth. But there are negative side effects to steroids. Once they stop taking the steroids there is the danger of experiencing a post cycle crash. Post cycle therapy or PCT is used to combat these negative side effects and avoid the crash. If you plan to take steroids you should plan your post cycle therapy in advance.

One of the reasons many people continue steroid use is because they suffered from a post cycle crash including muscle loss. To avoid this they would simply get back on steroids. But continued use of steroid use can cause problems. With the correct post cycle therapy you can stop steroid usage and not suffer as many negative side effects.

When you are using synthetic steroids your body is being given large amounts of testosterone. So much, that it stops producing its own testosterone or at the very least drastically slows production. Once you’re off your cycle your body will start producing testosterone again – but not right away.

Also, to combat the extra testosterone being produce while you’re on steroids, your body starts producing more estrogen. When you stop the steroids your body will still be producing the extra estrogen. This can cause unwanted side effects such as low sex drive, water retention and even breast production.

Because of these side effects; you want to get your hormones back into balance as quickly as possible. PCT helps get your body back into high gear. Without PCT, you can begin to lose the muscle mass you gained during your cycle.

PCT involves taking the following, HCG, Nolva and Clomid. These drugs help promote the production of testosterone until your body’s hormones are back in balance.

To reduce the amount of estrogen in your system, SERMS or Selective Estrogen Receptor Modulators are recommended. Two of the most popular are Clomiphene Citrate and Tamoxifen. These are usually started during the last few weeks of a steroid cycle and then continued for three or four weeks after.

PCT plans often include a cortisol suppressor. This is because anabolic steroids block the receptors in the muscles that normally take in cortisol. Your body will start producing more receptors to fight this. Without this your body can go into a catabolic state that depletes muscle tissue. This results in losing the muscle that you just gained during your cycle.

A good post cycle therapy plan will get your body back into hormonal balance as quickly as possible and reduce negative side effects. A forty-five day post cycle therapy is usually recommended. It’s important to also keep lifting weights and working out as you were before. This also helps prevent muscle loss.

You should also eat a healthy diet and be sure to get enough rest during your post therapy cycle. But for most users this is not enough to combat the side effects.

Tamoxifen Citrate (Nolva) is used to treat some types of breast cancer in men and women. It is also used to lower a woman's chance of developing breast cancer if she has a high risk (such as a family history of breast cancer. Since Tamoxifen Citrate (Nolva) has the ability of inhibiting the growth of tumors that respond to estrogens, it is one of the most popular drugs for treating node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The antiestrogen is also recommended for treating metastatic breast cancer in women and men and Tamoxifen citrate is an alternative to oophorectomy or ovarian irradiation in premenopausal women with metastatic breast cancer. Medically, it is advised for the treatment of breast cancer that has spread to other parts of the body (metastatic breast cancer) and is also advised to treat breast cancer in certain patients after surgery and radiation therapy and may even be suggested to minimize the chances of breast cancer in high-risk patients.

One of the biggest advantages of this antiestrogen is that patients whose tumors are estrogen receptor positive are more likely to benefit from it. In addition to that, it can minimize the occurrence of contralateral breast cancer in patients receiving adjuvant therapy for breast cancer. In women with Ductal Carcinoma in Situ (DCIS) after breast surgery and radiation, Nolva can minimize the risk of invasive breast cancer. It is worthwhile to note that Tamoxifen Citrate is well tolerated in males with breast cancer and safety profile of the drug in males is similar to that noticed in women.

Sportsmen using anabolic steroids and performance enhancing drugs like Dianabol, Anadrol and Testosterone derivatives often make use of Nolvadex and medical studies in the past have suggested that use of this antiestrogen is associated with dramatic improvements in levels of luteinizing hormone, follicle-stimulating hormone, testosterone, and estrogen control.  Since use of Nolva is featured by its mild yet highly effective properties, it is often preferred compared to Arimidex, Femara, and Aromasin since it does not prevent aromatization but plays the role of an estrogen antagonist, which is also useful in burning fat.

The recommended dose of Tamoxifen Citrate (Nolva) for patients with Ductal Carcinoma in Situ (DCIS) is 20 mg daily for 5 years while sportsmen on steroids use it in doses of 20-45 mg per day, with or without food.

Nolva abuse can lead to side effects, which may be mild or severe, including hypercalcemia, peripheral edema, distaste for food, pruritus vulvae, depression, dizziness, light-headedness, headache, hair thinning and partial hair loss, and vaginal dryness. In very rare cases, side effects like erythema multiforme, Stevens-Johnson syndrome, bullous pemphigoid, interstitial pneumonitis, and rare reports of hypersensitivity reactions including angioedema may happen.

Women keen to use Tamoxifen citrate (Nolva) should avoid getting pregnant for two months after last stopping its use and others should best use birth control methods that don’t use hormones like diaphragms with spermicide or plain intrauterine devices (IUDs). Moreover, breast-feeding is not recommended while using this drug as it is unknown of Tamoxifen Citrate passes into breast milk or may cause potential risk to the infant. Nolva is not recommended to individuals suffering with high amount of calcium in the blood, severely decreased platelets, decreased white blood cells, cataracts, problems with eyesight, blood clot in lung, stroke, obstruction of a blood vessel by a blood clot, blood clot in a deep vein, pregnancy, or a mother who is producing milk and breastfeeding. A loss of sexual ability or interest may occur in men making use of Nolva.

Medical advice should be sought on an immediate basis after stopping use of Tamoxifen Citrate (Nolva) if side effects such as pain or pressure in pelvis, vaginal bleeding, changes in the amount or timing of bleeding or increased clotting, sudden chest pain, shortness of breath, coughing up blood, pain, tenderness, or swelling in one or both of your legs , sudden trouble seeing in one or both eyes, sudden severe headache with no known cause, sudden trouble walking, dizziness, loss of balance or coordination, or lack of appetite and yellowing of your skin or whites of eyes is noticed after making use of the anti estrogen.

HIV-patients gain weight and muscle mass with steroids

People who are suffering from the dreaded HIV-virus and making use of anabolic steroids to prevent AIDS wasting tend to gain modest gains in terms of muscle mass and weight, according to a new review. Anabolic steroids are synthetic substances like to the masculine sex hormone testosterone that promote growth of skeletal muscle and the development of man sex characteristics. Although most recently in the news for their misuse by professional athletes, anabolic steroids have valid medical application for men with low testosterone and people with certain types of anemia. Two anabolic steroids available in the United States, nandrolone decanoate and oxandrolone, have been used to help increase weight and muscle mass in small studies of people with wasting. Conversely, anabolic steroid use has been associated with increased rates of HIV in those who share needles or use nonsterile needles when they inject steroids.

We were unable to assess these risks in our review due to the small duration of treatment in the studies. It is worth nothing that AIDS wasting results in considerable loss of cadaver weight in HIV-patients apart from muscle loss. It stems from human body’s inability to promote muscle growth and testosterone levels, which can be effectively handled with anabolic steroids.

AIDS wasting syndrome (cachexia) is a condition associated with advanced HIV disease. It involves overall weight loss, but more importantly, the loss of lean body mass, or muscle, which sometimes may be replaced by fat. Weight loss results from a number of factors, alone or in combination, including lack of appetite, nausea, diarrhea, oral problems that build eating hard, and problems related to intestinal absorption and use of nutrients. The condition was much more prevalent in the developed world before alliance antiretroviral remedy became available.

A correct diagnosis and the proper intervention for each individual are as important in treating AIDS wasting as they are for any other medical problem. Early intervention is often most successful, and a variety of effective and relatively inexpensive tools (such as nutritional supplements, appetite stimulants, and exercise) can be used. HGH is not a universal remedy for treating AIDS wasting. While it can have a dramatically beneficial effect in some individuals (presumably those with a deficiency of natural hGH), the majority may see no benefit. The current hGH regimen for AIDS wasting consists of a daily injection administered at bedtime to mimic the normal cycle of growth hormone release into the bloodstream. The portion is 4-6 mg, based upon body weight. HGH alone is likely to result in weight gain that is primarily overweight, while adding a regimen of resistance exercise, such as weight training, can help build lean cadaver mass.

HIV infection

HCV is a singular-stranded RNA virus that is transmitted mainly through blood exposure, and, less commonly, through perinatal or sex exposure. HCV is more likely than HIV to be transmitted via a blood borne way; there is an approximately 10-fold greater danger of HCV transmission after needle stick exposure compared with the risk of HIV transfer, and the concentrations of HCV in a given volume of blood are greater than those of HIV. Perinatal transmission of HIV is more likely among women who are co-infected with HIV and HCV than among women with HIV infection alone; similarly, perinatal transmission of HCV is more likely in co infected women than in those with HCV mono infection. Breast-feeding is not known to send HCV, although HIV-infected women are advised against breast-feeding because of the risk of transmitting HIV. Although reproductive transmission of HCV is not efficient, 10% of acutely infected HCV persons report no danger factor other than sexual contact with an HCV-infected partner. Many centers have reported an increase in acute HCV in MSM, and rates of sexual transmission of HCV appear to be higher in in MSM than in the general population, especially among persons who are co-infected with HIV. The natural history of HCV infection is variable. Nearly 20% of mono infected patients ultimately develop cirrhosis, whereas approximately 80% of patients develop some degree of fibrosis (without progression to cirrhosis); patients without cirrhosis typically remain asymptomatic. HCV can affect organ systems outside the liver, such as dermatological and renal systems, but its effects most commonly are restricted to the liver. Co infection with HIV adversely impacts the natural description of HCV infection. HIV/HCV-coinfected patients have lower rates of spontaneous HCV clearance, higher HCV viral loads, reduce rates of successful HCV treatment, faster advancement to cirrhosis, and greater danger of developing liver compensation, end-stage liver disease, and hepatocellular carcinoma (HCC). On the other hand, HCV co-infection does not appear to grow HIV- and AIDS-associated complications or the success of HIV antiviral (ARV) treatment.